Article
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2022
Mathieu Luckson N, Larkins Erin, Akinboro Oladimeji, Roy Pourab, Amatya Anup K, Fiero Mallorie H, Mishra-Kalyani Pallavi S, Helms Whitney S, Myers Claire E, Skinner Amy M, Aungst Stephanie, Jin Runyan, Zhao Hong, Xia Huiming, Zirkelbach Jeanne Fourie, Bi Youwei, Li Yangbing, Liu Jiang, Grimstein Manuela, Zhang Xinyuan, Woods Stacie, Reece Kelie, Abukhdeir Abdelrahmman M, Ghosh Soma, Philip Reena, Tang Shenghui, Goldberg Kirsten B, Pazdur Richard, Beaver Julia A, Singh Harpreet
Abstract excerpt
The FDA approved capmatinib and tepotinib on May 6, 2020, and February 3, 2021, respectively. Capmatinib is indicated for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Tepotinib is indicated for mNSCLC harboring MET exon 14 skipping alterations. The approvals were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.